The Prevalence of SEN Virus and Occult Hepatitis B (OBI) Virus Infection Among Blood Donors in Ahvaz City

Samaneh Abbasi,1,2 Manoochehr Makvandi,1,2,7 Gharib Karimi,2 and NilooFar Neisi2

1Health Research Institute, Infectious and Tropical Disease Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2Department of Virology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
7Corresponding author: Manoochehr Makvandi, Health Research Institute, Infectious and Tropical Disease Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran. Tel: +98-613354389, Fax: +98-613365444, E-mail: manoochehrmakvandi29@yahoo.com

Received 2016 February 23; Revised 2016 May 31; Accepted 2016 June 21.

Abstract

Background: The SEN virus (SENV) is a prevalent blood borne pathogen that has a worldwide incidence. SENV is comprised of eight genotypes; genotypes H and D are frequently associated with the pathogenesis of non-A - E hepatitis and post-transfusion hepatitis in blood donors and hepatitis patients. So far, no SENV pathogenesis has been reported in the liver biopsies of SENV carriers, but the frequency of SENV and its related genotypes requires further molecular epidemiology studies in different regions of the world. Occult hepatitis B infection (OBI) is another global public health problem that is primarily transmitted via blood transfusions. Therefore, the identification of OBI among blood donors is key to preventing the spread of this disease. The relationship between SENV and OBI requires further evaluation.

Objectives: The aim of this study was to determine the prevalence of SENV-D and SENV-H in blood donors in Ahvaz city with a particular focus on co-infection with OBI.

Patients and Methods: This study had a cross-sectional design and included 184 healthy consecutive blood donors who visited a blood transfusion center in Ahvaz city from October-November 2013. The sera of all blood donors negative for HBsAg, anti-HCV antibody, and anti-HIV antibody were tested for SENV-D and SENV-H using nested polymerase chain reaction (PCR). In addition, tests for HBV DNA (PCR), HBcIgG (ELISA), liver function (aspartate transaminase and alanine transaminase), and alkaline phosphatase were carried out.

Results: Liver function tests in the healthy blood donors were within the normal range. The incidence rates of SENV-D and SENV-H in the 184 total blood donors were 10 (5.4%) (95% confidence interval (CI): 2.1% - 9.0%) and 32 (17.4%) cases (95% CI: 12.0% - 23.0%), respectively. SENV-H/D co-infection occurred in 2 (1.1%) patients. The sera of 8/184 (4.3%) were positive for anti-HBc antibody but negative for HBV DNA.

Conclusions: Regardless of the presence of nonpathogenic SENV, 44/184 (24%) blood donors tested positive for both SENV-D and SENV-H. Although 4.3% of blood donors were positive for HBcIgG but negative for HBV DNA, the presence of OBI cannot be ruled out unless their liver biopsies show negative for HBV DNA.

Keywords: SEN Virus, Chronic Hepatitis B Infection, Transfusion Transmitted Virus, Blood Donor, Polymerase Chain Reaction

1. Background

Recent reports have described that the deoxyribonucleic acid (DNA) virus designated as the SEN virus (SENV) was first discovered in the serum of an intravenous drug user infected with human immunodeficiency virus (HIV) (1). The name for the SEN virus was derived from the initials of the first identified patient (2). SENV has been described as a blood borne infection with a small, circular, single-stranded, non-enveloped DNA virus that contains approximately 3800 nucleotides and belongs to the Circoviridae family, which also includes the Torque teno virus (TTV), TUS01, SANBAN, and YONBAN (3, 4). SENV is sub-grouped into eight distinct strains (A - H) (5, 6). According to previous studies, SENV genotypes H (SENV-H) and D (SENV-D) are the two genotypes suspected of being significantly associated with the pathogenesis of non-A - E hepatitis and also post-transfusion hepatitis (3, 6).

Currently, most investigations have focused on the SENV-H and SENV-D genotypes, which are dominant in different geographical regions of the world (3, 6). Interestingly, SENV is highly prone to mutation, which is a typical feature of RNA viruses but not DNA viruses; these mutations may result in a persistent state of SENV (3, 7). Further studies revealed that SENV characterization is similar to TTV (8). The SENV and TTV genomes have 55% and 37% homogeneity in their nucleotide and amino acid sequences, respectively (2, 3). SENV may be transmitted via a blood transfusion or through mother-to-child transmis-
sion (9, 10). The high prevalence of SENV observed among patients with HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) infections indicate a shared route of transmission (3, 7). As a result, non-transfused individuals are at low risk of contracting an SENV infection (2, 9). On recent study reported that the SENV DNA level was not higher in patients with liver diseases than it was in healthy blood donors (11). So far, the pathogenesis of SENV infection remains unknown, and the clinical relevance of SENV alone or in combination with other liver infections is controversial (12).

Occult HBV infection (OBI) is defined as the detection of HBV DNA in the sera or liver biopsy along with a negative result for the hepatitis B surface antigen (HBsAg) with or without anti-HBc or anti-HBs (13, 14). The identification of anti-HBc is important in the diagnosis of 80% of OBIs of HBV, which is noteworthy because enzyme-linked immunosorbent assay (ELISA) cannot detect the HBsAg in this region (14, 16). As a result, the screening of blood donors using ELISA will miss the OBI; therefore, the gold standard test for OBI detection is a molecular approach, including nested polymerase chain reaction (PCR) or real-time PCR (17). Several studies have suggested that OBI largely occurs in regions with high levels of endemic HBV infection (18). Persistent OBI may result in cirrhosis of the liver or hepatocellular carcinoma (19). In Iran, the incidence of HBV is intermediate, ranging from 1.6% - 3.6% (20, 21). The presence of OBI among blood donors has not yet been reported in Iran. Thus, this study was conducted to determine the incidence of SENV-D and SENV-H infection with a specific focus on OBI diagnosed in blood donors in Ahvaz city, the capital of the Khozestan province, which is located in southwest Iran.

2. Objectives

The aim of this study was to determine the prevalence of SENV-D and SENV-H with a particular focus on OBI diagnosed in blood donors in Ahvaz city, Iran.

3. Patients and Methods

3.1. Serum Samples

This study had a cross-sectional design and included 184 healthy blood donors from the Ahvaz blood transfusion center in Ahvaz city, Iran, from October-November 2013. The sera of all donors were negative for HBsAg, anti-HCV antibodies, and anti-HIV antibodies. All blood samples were also tested for SENV-D and SENV-H DNA using nested PCR. Liver function testing, including aspartate aminotransferase (AST) and alanine transaminase (ALT), and alkaline phosphatase (ALP), HBcIgG (ELISA, DIA.PRO, Italy), and HBV DNA (HbsAg gene) were carried out for each individual donor. This study was approved by the ethics committee of our institution and had the registration number 122 at the Ahvaz Jundishapur University of Medical Sciences. Informed consent was obtained from all participants before the study began. Demographic information was collected from each donor, including age, sex, educational level, living situation, and any history of blood transfusions, surgery, tattooing, cupping, and phlebotomy (Table 1). The following steps were carried out for the nested PCR.

3.2. DNA Extraction and Detection of SENV DNA Using Nested PCR

DNA extraction was carried out for all the sera using the high pure viral nucleic acid kit (Roche diagnostics, Germany) according to the manufacturer’s instructions. The extracted DNA was stored at -70°C prior to testing. The forward primer AI-1F (5’-TWYCMAACGACCAGCTAGACCT-3’) and the reverse primer AI-1R (5’-GTTTGTGTTAGCAGACAAGGA-3’) were used to amplify the target regions of the ORFi gene of SENV-D and SENV-H by nested PCR (4). For the first round, the 25-µl PCR reaction mixture contained 2.5 µl of a 10X PCR buffer, 0.2 pmol of each primer, 1.5 mM MgCl2, 200 mM dNTPs, 1 U of Smart Taq DNA polymerase (CinnaGen, Iran), and 5 µl of the extracted DNA.

All the samples, including the negative and positive controls, were subjected to a thermocycler (Peqlab, Germany) and programmed with the following conditions: 94°C for 5 minutes and 35 cycles, 94°C for 1 minute, 53°C for 1 minute, and 72°C for 1 minute with a final extension at 72°C for 10 minutes. For the second PCR round, 3 µl of the product from the first PCR round were used. The D-H48F (5’-CTAAGCAGCCCTAACAATCCAG-3’) and D-I34IR (5’-GCAGTTGACCGAAGTTAAGAGG-3’) primers were used for the SENV-D genotype. For the SENV-H genotype, forward primer H-I020F (5’-TTTGGCTGCCATTCCTCCAG-3’) and reverse primer H-I38R (5’-AGAATGATGGTGATGATGATG-3’) were used (4). The contents of the second PCR reaction mixture were similar to those used in the first round. The PCR conditions were programmed at 94°C for 5 minutes, 25 cycles of 94°C for 1 minute, 54°C for 1 minute, and 72°C for 1 minute. A final PCR product of 195 base pairs indicated a positive reactivity for SENV-D, while 119 base pairs revealed the same for SENV-H after appearing on 1.5% agarose gel electrophoresis supplemented with a DNA-safe stain (CinnaGen, Iran).
### Table 1. Demographic Characteristics of Blood Donors

| Variable                                      | SENV-pos variant (%) | SENV-neg (%) | Total No. (%) | P-Value |
|------------------------------------------------|----------------------|--------------|---------------|---------|
|                                                | D→H→D+H              |              |               |         |
| Age, years                                     |                      |              |               | 0.09    |
| < 30                                           | 1 (3.3)              | 4 (13.3)     | 0 (0)         | 25 (83.3) | 30 (16.3) |  |
| 30 - 40                                        | 4 (5.6)              | 11 (15.5)    | 0 (0)         | 56 (78.9) | 71 (18.6) |  |
| 40 - 50                                        | 2 (1.8)              | 9 (7.3)      | 0 (0)         | 41 (78.8) | 52 (28.3) |  |
| > 50                                           | 3 (9.7)              | 8 (25.8)     | 2 (6.5)       | 18 (58.1) | 31 (16.8) |  |
| Level of education                             |                      |              |               | 0.88    |
| Graduate diploma                               | 9 (6.4)              | 24 (17.1)    | 2 (1.4)       | 105 (75) | 140 (76.1) |  |
| AD or BS<sup>c</sup>                           | 1 (2.6)              | 8 (20.5)     | 0 (0)         | 30 (76.9) | 39 (21.2) |  |
| MSc or PhD<sup>d</sup>                         | 0 (0)                | 0 (0)        | 0 (0)         | 5 (100)  | 5 (2.7)    |  |
| Live                                           |                      |              |               | 0.27    |
| Ahvaz                                          | 6 (4)                | 27 (17.9)    | 2 (1.3)       | 116 (76.8) | 151 (82.1) |  |
| Other                                          | 4 (22.1)             | 5 (5.2)      | 0 (0)         | 24 (72.7) | 33 (17.9) |  |
| History of receiving blood transfusions and blood components |                      |              |               | 0.17    |
| Yes                                            | 1 (33.3)             | 0 (0)        | 0 (0)         | 2 (66.7) | 3 (1.6)    |  |
| No                                             | 9 (5)                | 32 (77.7)    | 2 (1.3)       | 138 (76.2) | 181 (98.4) |  |
| History of abandonment of addiction (fumigation, eating, or injection) |                      |              |               | 0.88    |
| Yes                                            | 0 (0)                | 0 (0)        | 0 (0)         | 2 (100)  | 2 (1.1)    |  |
| No                                             | 10 (5.5)             | 32 (77.6)    | 2 (1.3)       | 138 (75.8) | 182 (98.9) |  |
| History of infectious diseases (HBV or HCV)    |                      |              |               | 0.95    |
| Yes                                            | 0 (0)                | 0 (0)        | 0 (0)         | 1 (100)  | 1 (0.5)    |  |
| No                                             | 10 (5.5)             | 32 (77.5)    | 2 (1.3)       | 139 (76) | 183 (99.5) |  |
| History of endoscopic surgery, tattooing, cupping, or phlebotomy |                      |              |               | 0.31    |
| Yes                                            | 5 (10.2)             | 8 (16.3)     | 1 (2)         | 35 (74.4) | 49 (26.6) |  |
| No                                             | 5 (3.7)              | 24 (78.6)    | 1 (0.7)       | 105 (77.8) | 135 (74.4) |  |

<sup>a</sup>All blood donors were male. The sera of 8/184 (4.3%) were positive for anti-HBc antibody (2 (4.5%) were SENV-positive, and 6 (4.3%) were SENV-negative), but all were negative for HBV DNA.

<sup>b</sup>P < 0.05 was considered significant.

<sup>c</sup>Associate degree or bachelor degree.

<sup>d</sup>Masters degree or doctor of philosophy.

### 3.3. Nested PCR for HBV DNA

Nested PCR was used to detect HBV DNA in the sera of all blood donors. For the first round, forward primer SA1 (5′-ATCGCTGGATGTGTCTGCGG-3′) and reverse primer SA2 (5′-GGCAACGGGGTAAAGGCTCA-3′) were used (22). The 25-μL PCR reaction mixture contained 7 μL of the template, 2.5 μL of the 10X PCR reaction buffer, 1 μL dNTP (10 mM), 0.75 μL MgCl2 (50 mM), 0.5 μL forward/reverse primer, 0.2 Taq DNA polymerase (CinnaGen, Iran), and 12.5 μL water. The negative, positive, and control samples were subjected to a thermocycler (Peqlab, Germany) at 94°C for 5 minutes and 35 cycles, 94°C for 1 minute, 54°C for 1 minute, 72°C for 1 minute, and a final extension at 72°C for 10 minutes. For the second round, 5 μL of the first-round product was used for the template, and the inner forward primer SB1 (5′-TTAGGTTTAAATGTATACCC-3′) and inner reverse primer SB2 (5′-CATCTTCTGTGTTCTCTCG-3′) were used (22). The PCR reaction mixture contents were similar to those used in the first round, and the following PCR conditions were programmed: 94°C for 5 minutes, 30 cycles at 94°C for 1 minute, 45°C for 1 minute, 72°C for 1 minute, and a final extension at 72°C for 10 minutes. The PCR products were analyzed on 1.5% agarose gel electrophoresis stained with a DNA-safe stain (CinnaGen, Iran) and photographed under ultraviolet light. The presence of a PCR product with 416 base pairs indicated a positive reaction.
3.4. DNA Sequencing

Ten positive PCR products of SENV were randomly selected, purified, and sent for sequencing by 1st BASE laboratories in Malaysia.

4. Results

All blood donors were male, and their ages ranged from 30 - 62 years, with a mean age of 40 ± 9.4 years. AST, ALT, and ALP results among the healthy blood donors were within the normal range. The results of the nested PCR following agarose gel electrophoresis indicated a 195-base pair band for SENV-D and a 119-base pair band for SENV-H (Figure 1). The incidence rates of SENV-D and SENV-H among the blood donors were 10/184 (5.4%) (95% confidence interval (CI): 2.1% - 9%) and 32/184 (17.4%) (95% CI: 12% - 23%), respectively. There were 2 (1.1%) coinfection cases of both SENV-H and SENV-D among the blood donors. SENV viremia was identified in 44 (24%) of the 184 blood donors (95% CI: 18% - 30%). The prevalence of SENV-H was 3.2-fold higher than that of SENV-D in healthy blood donors. The incidence of anti-HBc antibody was 8/184 among the blood donors (4.3%).

All the blood donors’ sera, including those positive for the anti-HBc antibody, were negative for HBV DNA. Thus, OBI was not detected among the blood donors. The results of homology sequencing of SENV-D and SENV-H in the 10 samples varied from 91% - 100%. The sequence homology was 91% among the isolated SENV-D cases (GenBank: accession numbers AB856069.1 and GQ179970.1), while the sequence homology was 100% among the isolated SENV-H patients (GenBank: accession numbers GQ452051.1 and GQ452053.1). The prevalence of SENV and variables such as age, education, location, and history of blood transfusion and surgical endoscopy, were not significant (P > 0.05) (Table 1).

5. Discussion

In our study, SENV-D and SENV-H had an incidence of 5.4% and 17.4%, respectively, among healthy blood donors. Two (1.1%) blood donors had co-infection with SENV-D and SENV-H variants. Overall, 44 (24%) of the blood donors were positive for both SENV-D and SENV-H viruses. Our results are consistent with the findings of 24% SENV-D and SENV-H reported in Greece (23) and also the results of 23.08% that were reported by Sharifi et al. in Tehran in 2008 (24). The prevalence of SENV strains D and H among healthy blood donors varied from a low of 1.5% in the United States (7) to a high of 90.8% in Iran (25). The incidence of SENV has also been reported in China (31%), (26), Japan (10% - 22%) (10, 27), Germany (17%) (28), Taiwan (13%) (29), Italy (13%) (30), and Thailand (5%) (31). Out of the eight possible SENV variants, most studies have focused on the SENV-H and SENV-D variants because they are the only two blood borne viruses (7, 10, 26). In our study, only 1 (2.3%) of the 44 donors who were positive for SENV had a history of blood transfusion; the remaining 43 (97.7%) did not. The prevalence of SENV-H was also 3.2-fold higher than that of SENV-D in healthy blood donors. In some recent studies, the prevalence of SENV-H was 10 times higher than the SENV-D variant in patients with chronic hepatitis B or C and also in patients with non-A - E hepatitis (7, 8, 29).

In our study, regardless of the incidence of 24% SENV cases, no liver function test abnormalities (AST and ALT) and or abnormal ALP levels were observed among the healthy blood donors. However, no pathogenesis of SENV in the liver biopsies has been reported. Co-infection with SENV and other viral hepatitis infections (HBV and HCV) has been observed in high-risk group patients and also in healthy blood donors (3, 25, 26). In 2010, Karimi-Rastehkenari et al. reported that the frequency of SENV-H or SENV-D and co-infections of HBV or HCV were significantly higher among thalassemic patients (98%) than in healthy individuals (90.8%) in Iran (25). Kao et al. concluded that the rate of SENV-D and SENV-H in thalassemic patients (90%) was greater than that of parenteral drug users (54%), hemophilic patients (68%), and hemodialysis patients (68%) (29).

Therefore, the outcomes of these aforementioned
The authors wish to thank the head and personnel of the Infectious and Tropical diseases research center of Ahvaz Jundishapur University of Medical Sciences in Ahvaz, Iran, for their approval and financial support.

Footnotes

Authors’ Contribution: Manoochehr Makvandi, study design, funding, and manuscript preparation; Samaneh Abbasi, conducting experiments, data analysis, interpretation of the results; Niloofar Neisi, conducting experiments; Gharib Karimi, blood donor provisions.

Financial Disclosure: The authors have no financial interests to disclose related to the material in the manuscript.

Funding/Support: The current study was conducted under registration No. 9123 and ethics committee registration no. 122 at Ahvaz Jundishapur University of Medical Sciences in Ahvaz, Iran. This study was supported by the health research institute, infectious and tropical disease research center at Ahvaz Jundishapur University of Medical Sciences in Ahvaz, Iran.

References

1. Primi D, Fiordalisi G, Mantero G, Mattioli S, Sottini A, Bonelli F, et al. Identification of SEN virus genotypes. 2000.; 108:223–8. doi: 10.1179/2047773214Y.0000000144. [PubMed: 15098715].

2. Akiba J, Umemura T, Alter HJ, Kojoro M, Tabor E. SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. 2005;48(7):1014–4. doi: 10.1086/1537-2995.2004.00209.x. [PubMed: 15987151].

3. Dehkhordi P, Doosti A. The prevalence of SEN virus infection in blood donors and chronic hepatitis B and C patients in Chaharmahal Va Bakhtiari province. cell animal biol. 2015(8):182–6.

4. Kojima H, Kaida KD, Zhang M, Giulivi A, Minuk GY. Genomic analysis of a recently identified virus (SEN virus) and genotypes D and H by polymerase chain reaction. Antiviral Res. 2005;65(1):27–3. [PubMed: 14516919].

5. Tang ZH, Chen XB, Yu YS, Zang GQ. Prevalence and clinical significance of SEN virus infection in patients with non-A-E hepatitis and volunteer blood donors in Shanghai. World J Gastroenterol. 2008;14(26):4204–8. [PubMed: 18636667].

6. Cakaloglu Y, Akyuz F, Bozaci M, Ibrisim D, Pinarbasi B, Demir K, et al. Prevalence and clinical significance of SEN-H virus in chronic hepatitis B, C and delta infections in Turkey. Turk J Gastroenterol. 2008;39(2):103–4. [PubMed: 19100685].

7. Umemura T, Yee AE, Sottini A, Moratto D, Tanaka Y, Wang RY, et al. SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology. 2001;33(5):1303–11. doi: 10.1053/jhep.2001.24268. [PubMed: 11342650].

8. Davidson F, MacDonald D, Mokili JL, Prescott LE, Graham S, Simmonds P. Early acquisition of TT virus (TTV) in an area endemic for TTV infection. J Infect Dis. 1999;179(5):1070–6. doi: 10.1086/34730. [PubMed: 10912096].

9. Omar M, El-Din SS, Fam N, Diab M, Shemis M, Raafat M, et al. SEN virus infection in Egyptian patients with chronic hepatitis C and patients undergoing hemodialysis. Medscape J Med. 2008;10(12):2490. [PubMed: 19242596].

10. Shibata M, Wang RY, Yoshihara M, Shih JW, Alter HJ, Mitamura K. The presence of a newly identified infectious agent (SEN virus) in patients with liver diseases and in blood donors in Japan. J Infect Dis. 2001;184(4):400–4. doi: 10.1086/322050. [PubMed: 11471096].

11. Yoshida H, Kato N, Shiritori Y, Shao R, Wang Y, Shima S, et al. Weak association between SEN virus viremia and liver disease. J Clin Microbiol. 2002;40(9):3140–5. [PubMed: 12202544].

12. Sugiyama T, Goto K, Imamine H, Ando T, Inaka K, Sugiyama T, et al. Prevalence of SEN virus among children in Japan. Virus Res. 2004;100(2):223–8. doi: 10.1016/j.virusres.2003.12.028. [PubMed: 15092420].

13. Allain JP, Cox L. Challenges in hepatitis B detection among blood donors. Curr Opin Hematol. 2011;18(6):461–6. doi: 10.1097/MOH.0b013e32834ba1c0. [PubMed: 2192252].

14. Gonzalez R, Torres P, Castro E, Barbolla L, Candotti D, Koppelman M, et al. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain. Transfusion. 2010;50(1):221–30. doi: 10.1111/j.1537-2995.2009.02341.x. [PubMed: 1982332].

15. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2(8):479–86. [PubMed: 12150847].

16. Gerlich WH, Wagner FF, Chudy M, Harristsou L, Lattermann A, Wienek S, et al. HBsAg non-reactive HBV infection in blood donors: Transmission and pathogenicity. Med Virol. 2007;79(5):532–6.

17. Nga E, Mbamalu C, Ekejindu I. Occult hepatitis B viral infection among blood donors in South-Eastern Nigeria. Pathog Glob Health. 2014;108(5):223–8. doi: 10.1179/204773214Y.0000000044. [PubMed: 24995918].
18. Alavian SM, Jazayeri SM. Occult Hepatitis B infection (OBI) in vaccinated groups, a metanalysis. *Arch Med Laboratory Sci*. 2015;4(2).
19. Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. *World J Gastroenterol*. 2014;20(20):5951-61. doi: 10.3748/wjg.v20.i20.5951. [PubMed: 24876788].
20. Alavian SM. Ministry of Health in Iran is serious about controlling occult hepatitis B infection. *J Microbiol*. 2007;9(3):5-35.
21. Malekzadeh R, Khatibian M, Rezvan H. Viral hepatitis in the world and Iran. *J Iran Med Council*. 1997;2:183-300.
22. Kumar GT, Kazim SN, Kumar M, Hissar S, Chauhan R, Basir SF, et al. Hepatitis B virus genotypes and hepatitis B surface antigen mutations in family contacts of hepatitis B virus infected patients with occult hepatitis B virus infection. *J Gastroenterol Hepatol*. 2009;24(4):588-98. doi: 10.1111/j.1440-1746.2008.05727.x. [PubMed: 19207682].
23. Umemura T, Tanaka E, Ostapowicz G, Brown KE, Heringlake S, Tassteer M, et al. Clinical significance of SEN virus infection in patients on maintenance hemodialysis. *Mol Shell Virol*. 2010;17(1):3-5. doi: 10.3748/wjg.v17.i1.3. [PubMed: 19285028].
24. Sharifi Z, Mahmoudian-Shooshtrimi A, Talebian A. The prevalence of SEN virus infection in blood donors in Iran. *Arch Iran Med*. 2009;12(4):422-6. [PubMed: 18588375].
25. Karimi-Rastehkenari A, Bouzari M. High frequency of SEN virus infection in thalassemic patients and healthy blood donors in Iran. *Virology*. 2016;7(1):3-5. doi: 10.1086/674389. [PubMed: 1667086].
26. Mu SJ, Du J, Zhan LS, Wang HP, Chen R, Wang QL, et al. Prevalence of a newly identified SEN virus in Taiwan. *Arch Med Laboratory Sci*. 2009;16(10):2402-5. doi: 10.1186/1743-422X-7-204. [PubMed: 20799931].
27. Kobayashi N, Tanaka E, Umemura T, Matsumoto A, Iijima T, Higuchi M, et al. Clinical significance of SEN virus infection in patients on maintenance haemodialysis. *Nephrol Dial Transplant*. 2003;18(2):348-52. [PubMed: 12543801].
28. Schroter M, Laufs R, Zollner B, Knodler B, Schafer P, Feucht HH. A novel DNA virus (SEN) among patients on maintenance hemodialysis: prevalence and clinical importance. *J Clin Virol*. 2003;27(1):69-73. [PubMed: 12727531].
29. Kao JH, Chen W, Chen Pj, Lai MY, Chen DS. Prevalence and implication of a newly identified infectious agent (SEN virus) in Taiwan. *Infect Dis*. 2002;185(3):389-92. doi: 10.1086/338472. [PubMed: 11807722].
30. Pirovano S, Bellinzoni M, Matteelli A, Ballerini C, Albertini A, Imberti L. High prevalence of a variant of SENV in intravenous drug user HIV-infected patients. *J Med Virol*. 2002;66(1):18-23. doi: 10.1002/jmv.10165. [PubMed: 12210426].
31. Tangkijvichian P, Theamboonlers A, Sriponthong M, Thong-Ngam D, Kullavanijaya P, Poovorawan Y. SEN virus infection in patients with chronic liver disease and hepatocellular carcinoma in Thailand. *J Gastroenterol Hepatol*. 2003;18(2):142-8. doi: 10.1111/j.1440-1746.2003.tb00002.x. [PubMed: 12640527].
32. Simmonds P, Prescott LE, Logue C, Davidson F, Thomas AE, Ludlam CA. TT virus-part of the normal human flora?. *J Infect Dis*. 1999;180(3):3748-50. doi: 10.1086/351053. [PubMed: 10516086].
33. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. *J Hepatol*. 2009;51(4):798-809. doi: 10.1016/j.jhep.2009.05.020. [PubMed: 19905780].
34. Norder H, Hammas B, Larsen J, Skaug K, Magnus I. Detection of HBV DNA by PCR in serum from an HBsAg negative blood donor implicated in cases of post-transfusion hepatitis B. *Arch Virol Suppl*. 2002;4:116-8. doi: 10.1007/s00535-003-0281-2. [PubMed: 14506788].
35. Hu KQ. Occult hepatitis B virus infection and its clinical implications. *J Viral Hepat*. 2009;16(4):243-57. doi: 10.1111/j.1537-2995.2009.02245.x. [PubMed: 19957477].
36. Panighrahi R, Biswas A, Datta S, Banerjee A, Chandra PK, Mahapatra PK, et al. Anti-hepatitis B core antigen testing with detection and characterization of occult hepatitis B virus by an in-house nucleic acid testing among blood donors in Behrampur, Ganjam, Orissa in southeastern India: implications for transfusion. *Virology*. 2009;390(2):204. doi: 10.1016/j.virol.2009.02.024. [PubMed: 19799931].
37. Kafi-abad SA, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. *Transfusion*. 2009;49(1):22-20. doi: 10.1111/j.1537-2995.2009.02245.x. [PubMed: 19527477].
38. Garcia-Montalvo BM, Ventura-Zapata LP. Molecular and serological characterization of occult hepatitis B infection in blood donors from Mexico. *Ann Hepatol*. 2011;10(2):133-41. [PubMed: 21502674].
39. Wang JT, Wang TH, Sheu JC, Shih LN, Lin JT, Chen DS. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteers with negative hepatitis B surface antigen. *J Infect Dis*. 1994;169(2):397-9. [PubMed: 7274531].
40. Wang D, Tan D, Cao X. [A prospective study of posttransfusion hepatitis B virus infection]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi*. 2000;14(5):77-9. [PubMed: 11503032].